I-Mab Files 2024 Annual Report
Ticker: NBP · Form: 20-F · Filed: Apr 3, 2025 · CIK: 1778016
| Field | Detail |
|---|---|
| Company | I-Mab (NBP) |
| Form Type | 20-F |
| Filed Date | Apr 3, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: annual-report, pharmaceuticals, licensing
TL;DR
I-Mab's 2024 20-F is in, check out the details on stock plans and the AbbVie deal.
AI Summary
I-Mab filed its 20-F for the fiscal year ending December 31, 2024, reporting on its operations and financial status. The company, incorporated in E9 and headquartered in Rockville, MD, is involved in the Pharmaceutical Preparations industry. Key events and financial data from 2022 through 2024 are referenced, including details on stock incentive plans and licensing agreements, such as the Lemzoparlimab License with AbbVie.
Why It Matters
This filing provides investors with a comprehensive overview of I-Mab's financial health, operational performance, and strategic developments for the past fiscal year, crucial for investment decisions.
Risk Assessment
Risk Level: medium — As a pharmaceutical company with significant licensing agreements, I-Mab faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2024-12-31 — Fiscal Year End (The period covered by the 20-F filing.)
- 2025-04-03 — Filing Date (The date the 20-F was submitted to the SEC.)
- 2022-08-01 — Lemzoparlimab License Start (Indicates the period related to the AbbVie licensing agreement.)
Key Players & Entities
- I-Mab (company) — Filer of the 20-F report
- 2024-12-31 (date) — Fiscal year end for the report
- Rockville, MD (location) — Business and mail address
- AbbVie (company) — Partner in Lemzoparlimab License agreement
- Lemzoparlimab License (agreement) — Key licensing agreement mentioned
FAQ
What is the primary business of I-Mab?
I-Mab is primarily involved in the Pharmaceutical Preparations industry, as indicated by its Standard Industrial Classification code [2834].
When was the 20-F report filed?
The 20-F report was filed on April 3, 2025.
What is the fiscal year end for I-Mab?
I-Mab's fiscal year ends on December 31st.
Which company is mentioned in relation to the Lemzoparlimab License?
AbbVie is mentioned in relation to the Lemzoparlimab License.
Where is I-Mab's business address?
I-Mab's business address is Suite 400, 2440 Research Blvd, Rockville, MD 20850.
Filing Details
This Form 20-F (Form 20-F) was filed with the SEC on April 3, 2025 regarding I-Mab (NBP).